4-(endo-spiro[8-azabicyclo[3.2.1]octane-3,2'-oxiran]-8-yl)naphthalene-1-carbonitrile | 870889-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-(endo-spiro[8-azabicyclo[3.2.1]octane-3,2'-oxiran]-8-yl)naphthalene-1-carbonitrile
• CAS: 870889-23-9
• 化学式: C₁₉H₁₈N₂O
• 分子量: 290.365
• InChiKey: JAFHNWRKQAWNCQ-QWHZDKJVSA-N

反应信息

• 作为反应物：
  描述：

  4-(endo-spiro[8-azabicyclo[3.2.1]octane-3,2'-oxiran]-8-yl)naphthalene-1-carbonitrile 在 硫酸 作用下， 以 四氢呋喃 、 水 为溶剂， 以31%的产率得到4-(3-endo-hydroxy-3-exo-hydroxymethyl-8-azabicyclo[3.2.1]oct-8-yl)naphthalene-1-carbonitrile
  参考文献：
  名称：

  Synthesis, Structure−Activity Relationships, and Characterization of Novel Nonsteroidal and Selective Androgen Receptor Modulators

  摘要：

  Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.

  DOI：

  10.1021/jm901149c
• 作为产物：
  描述：

  4-(3-oxo-8-azabicyclo[3.2.1]oct-8-yl)naphthalene-1-carbonitrile 、 三甲基碘化亚砜 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 以61%的产率得到4-(endo-spiro[8-azabicyclo[3.2.1]octane-3,2'-oxiran]-8-yl)naphthalene-1-carbonitrile
  参考文献：
  名称：

  Synthesis, Structure−Activity Relationships, and Characterization of Novel Nonsteroidal and Selective Androgen Receptor Modulators

  摘要：

  Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.

  DOI：

  10.1021/jm901149c

文献信息

• Androgen receptor modulators and methods of treating disease using the same
  申请人：Schlienger Nathalie

  公开号：US20070004679A1

  公开（公告）日：2007-01-04

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文公开了一种公式（I）的双环芳基化合物，其选择性调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及包括向需要治疗的患者给予公式（I）化合物的治疗疾病的方法。
• Androgen receptor modulators and method of treating disease using the same
  申请人：Schlienger Nathalie

  公开号：US20060014739A1

  公开（公告）日：2006-01-19

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文公开了式(I)的双环芳基化合物，其选择性调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及通过向需要治疗的患者施用式(I)化合物的方法治疗疾病。
• ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME
  申请人：Schlienger Nathalie

  公开号：US20080009489A1

  公开（公告）日：2008-01-10

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文披露了公式(I)的双环芳基化合物，其有选择性地调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及治疗疾病的方法，包括向需要该化合物的患者施用公式(I)的化合物。
• US7268232B2
  申请人：——

  公开号：US7268232B2

  公开（公告）日：2007-09-11
• [EN] ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME<br/>[FR] MODULATEURS DES RECEPTEURS D'ANDROGENES ET METHODES DE TRAITEMENT DE MALADIES UTILISANT CEUX-CI
  申请人：ACADIA PHARM INC

  公开号：WO2005115361A2

  公开（公告）日：2005-12-08

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.